Dropsophila tumor necrosis factor class molecule (“DmTNFv2”)
US7288632B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2005 |
| Grant date | Oct 30, 2007 |
| Priority date | — |
| Expiry date | Nov 11, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2217/05
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides novel polynucleotides encoding Drosophila DmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and homologs thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, in addition to methods of genetically modifying Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.